Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Tislelizumab(neoadjuvant)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinomas
1 trial -
Tocilizumab 162 mg
Hoffmann-La Roche
Rheumatoid Arthritis
1 trial -
Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB
Eli Lilly Co.
Systemic Juvenile Idiopathic Arthritis
1 trial -
Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf
Vera Therapeutics
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
1 trial -
Tora-Dol 30 mg/ml soluzione iniettabile, Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, SODIO CLORURO 0,9% BAXTER Soluzione per infusione
Fondazione Telethon ETS
Patients scheduled for major surgery for oncologic indication
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
2 trials -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non Small Cell Lung Cancer
1 trial -
Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie
Lacuna Pharma Pty Ltd
Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy
1 trial -
Tozorakimab
AstraZeneca
Viral Lung Infection and Acute Respiratory Failure
1 trial -
Tozorakimab 1
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tozorakimab, -, SALBUTAMOL, Tozorakimab-placebo
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tozorakimab, Tozorakimab-placebo
AstraZeneca AB
Severe viral lung infections
1 trial -
Tozorakimab-placebo, Tozorakimab, SALBUTAMOL
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Trabectedin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ovarian Cancer
1 trial -
Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection
INTENSITY THERAPEUTICS, INC.
liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma
1 trial -
Tradipitant
Lacuna Pharma Pty Ltd
Idiopathic or diabetic gastroparesis with moderate to severe nausea.
1 trial -
Trastuzumab
Mylan IRE Healthcare Limited
Breast Cancer
1 trial -
Trastuzumab
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial -
Trastuzumab
Celltrion Healthcare Australia Pty Ltd
HER2-positive Carcinoma of Breast
1 trial -
Trastuzumab Deruxtecan
AstraZeneca
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
AstraZeneca
Breast Neoplasms
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Ovarian Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Gastric Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources